Mancini Anthony 4
4 · Revolution Medicines, Inc. · Filed May 28, 2026
Research Summary
AI-generated summary of this filing
Revolution Medicines (RVMD) CCO Anthony Mancini Sells Shares, Exercises Options
What Happened
Anthony Mancini, Chief Global Commercialization Officer at Revolution Medicines (RVMD), exercised stock options to acquire 3,121 shares at $33.62 each (cash paid: $104,928) on May 26, 2026. On the same day he sold 3,121 shares in multiple open-market transactions under a pre-established 10b5-1 plan, generating total proceeds of approximately $480,611 (sales executed at weighted-average prices shown below). The activity includes the conversion/settlement of the derivative (exercise) and immediate disposals.
Key Details
- Transaction date: 2026-05-26 (Form 4 filed 2026-05-28 — timely)
- Option exercise (Code M): 3,121 shares acquired at $33.62 — $104,928 total.
- Sales (Code S): 700 shares @ $153.30 = $107,312; 2,000 shares @ $154.06 = $308,122; 421 shares @ $154.82 = $65,177. Total proceeds ≈ $480,611.
- Derivative line: 3,121 shares reported as disposed at $0.00 reflects the equity conversion related to the option exercise.
- Sales executed under a 10b5-1 trading plan adopted December 24, 2025 (Footnote F1). Several trades were executed in multiple fills; reported prices are weighted averages (Footnotes F3–F5).
- Holdings after the transactions are not specified in the provided extract; filing notes holdings include 54,400 restricted stock units (Footnote F2). Vesting schedule for the option is described in Footnote F6.
Context
This was an option exercise paired with immediate sales (common mechanics include using a 10b5-1 plan to sell shares after exercising). The exercise lowered the strike exposure (purchase at $33.62) while the sales monetized shares at market prices (~$153–$155). The presence of a 10b5-1 plan indicates the sales were pre-arranged and routine; no inference about insider sentiment should be made from this single filing.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1][F2]2026-05-26$33.62/sh+3,121$104,928→ 57,521 total - Sale
Common Stock
[F1][F3][F2]2026-05-26$153.30/sh−700$107,312→ 56,821 total - Sale
Common Stock
[F1][F4][F2]2026-05-26$154.06/sh−2,000$308,122→ 54,821 total - Sale
Common Stock
[F1][F5][F2]2026-05-26$154.82/sh−421$65,177→ 54,400 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F6]2026-05-26−3,121→ 106,109 totalExercise: $33.62Exp: 2035-03-31→ Common Stock (3,121 underlying)
Footnotes (6)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025.
- [F2]Includes 54,400 Restricted Stock Units.
- [F3]This transaction was executed in multiple trades at prices ranging from $152.64 to $153.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This transaction was executed in multiple trades at prices ranging from $153.65 to $154.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F5]This transaction was executed in multiple trades at prices ranging from $154.70 to $154.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F6]Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.